Our latest study, just published in @TheLancet, reports the first successful transition from porcine kidney #xenotransplantation to human kidney transplantation.
A genetically engineered pig kidney provided >9 months (271 days) of dialysis-free kidney function before successful human transplantation, supporting xenotransplantation as a potential bridge while preserving future transplant options.
Beyond the clinical milestone, the study provides new insights into late microvascular inflammation and innate immune activation that will help shape future immunosuppressive strategies and donor genetic engineering.
Link to article: https://t.co/RCZFq2w5vD
@mgh_transplant@MGHSurgery@MGBResearchNews@MGBKidneys@eGenesisBio
Could APOL1 risk variants affect kidney health before birth? In a HIVAN mouse model, APOL1-G1 was linked to a preeclampsia-like phenotype and reduced podocyte and glomerular densities in offspring, suggesting a developmental “second hit.” #ASNKidney360#BasicResearch https://t.co/qyM76NWEv7
Oh look, a list of the 25 Best Nephrology podcasts.
My thumbs are so tired, I hope I don’t have to scroll too far to find Freely Filtered and Channel Your Enthusiasm
😏
https://t.co/sTcslAQy6H
The GLP-1 drugs have evidence for beneficial impact— heart, kidney, liver, joints, immune system, and brain—that are independent of weight loss
@Cell_Metabolism@DanielJDrucker
https://t.co/ApB9ptjDL2
@NephRodby Preliminary data showed that ravulizumab was associated with a 43% reduction in proteinuria in patients with IgAN compared with placebo.
#Glomconhawaii
https://t.co/zpBcUcIcxO
#KDOQI US Commentary on the @goKDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis
https://t.co/1I0Avn7D4O (FREE)
@SaynaNorouzi
🧵 1/
From #GlomConHawaii LBCT 1st session: eGFR results at 24 months from VISIONARY trial by @DanaRizk1
💡Main question: Does sibeprenlimab preserve kidney function in IgAN?
Reminder by @VladoPerkovic
📍Sibeprenlimab inhibits APRIL, reducing pathogenic Gd-IgA1 production
📍VISIONARY was a ph 3 RCT, N=510; sibeprenlimab 400 mg SC vs placebo
Statement on behalf of UEFA and its 55 National AssociationStatement on behalf of UEFA and its 55 National AssociationStatement on behalf of UEFA and its 55 National AssociationStatement on behalf of UEFA and its 55 National Associations
Good morning from #ATC2026Boston@ATCMeeting where @TuftsMedicine's @HecmagsMD moderates the Interactive Symposium: Enhancing Access, Counseling and Management for Today's Living Kidney Donor. 7:00am, Room 256, Level 2.
Dr. @ArpitaBasu_ is kicking off #ATC2026Boston with the In-Depth Symposium, “Overcoming Age and Frailty Barriers to Improve Access to Transplantation.”